RxDoctor Payments Data

Shawn Hayes, MD

Internal Medicine · Lynchburg, VANPI 1871518076

Payments from drug & device makers

$1,557in general payments, 2019–2025

Across 27 payments — averaging $57.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$303
  • Novo Nordisk$227
  • AstraZeneca$225
  • AbbVie$223
  • Abbott$145
  • Organogenesis Inc.$122
  • plus $313 from 3 others

What the payments were for

  • Food & beverage$1,557100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,557 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$260,154
Medicare patients
605
Services billed
4,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$110,721
JanuviaSitagliptin Phosphate37$43,502
OzempicSemaglutide31$39,961
JardianceEmpagliflozin29$31,559
FarxigaDapagliflozin Propanediol28$27,909
VraylarCariprazine Hcl15$20,886
LinzessLinaclotide18$18,202
XareltoRivaroxaban29$18,180
JanumetSitagliptin Phos/Metformin Hcl11$13,687
TradjentaLinagliptin17$13,087
SymbicortBudesonide/Formoterol Fumarate24$11,648
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$9,575
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm36$9,185
Combivent RespimatIpratropium/Albuterol Sulfate11$8,608
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$8,359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Linzess, Synthroid$223$41,41968 claims
Novo NordiskOzempic$227$39,96131 claims
AstraZenecaFarxiga, Symbicort$225$39,55752 claims
Johnson & JohnsonXarelto$303$18,18029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →